Companies › Purespring Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PS-002 Adeno-associated viral vector delivering Complement Factor I (CFI) gene to correct complem | CFI | Phase 1 | Immunoglobulin A (IgA) Nephropathy | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07182227 | PS-002 | Phase 1 | Immunoglobulin A (IgA) Nephropathy | Genitourinary | Sep 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.